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Abstract
To identify predictive biomarkers for clinical responses to bortezomib treatment, 0.06 mL of
each whole blood without any cell separation procedures was stimulated ex vivo using five
agents, and eight mRNAs were quantified. In six centers, heparinized peripheral blood was
prospectively obtained from 80 previously treated or untreated, symptomatic multiple mye-
loma (MM) patients with measurable levels of M-proteins. The blood sample was procured
prior to treatment as well as 2-3 days and 1-3 weeks after the first dose of bortezomib,
which was intravenously administered biweekly or weekly, during the first cycle. Six stimu-
lant-mRNA combinations; that is, lipopolysaccharide (LPS)-granulocyte-macrophage col-
ony-stimulating factor (GM-CSF), LPS-CXCL chemokine 10 (CXCL10), LPS-CCL
chemokine 4 (CCL4), phytohemagglutinin-CCL4, zymosan A (ZA)-GMCSF and ZA-CCL4
showed significantly higher induction in the complete and very good partial response group
than in the stable and progressive disease group, as determined by both parametric (t-test)
and non-parametric (unpaired Mann-Whitney test) tests. Moreover, LPS-induced CXCL10
mRNA expression was significantly suppressed 2-3 days after the first dose of bortezomib
in all patients, as determined by both parametric (t-test) and non-parametric (paired Wil-
coxon test) tests, whereas the complete and very good partial response group showed sus-
tained suppression 1-3 weeks after the first dose. Thus, pretreatment LPS-CXCL10mRNA
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and/or the six combinations may serve as potential biomarkers for the response to bortezo-
mib treatment in MM patients.
Introduction
The proteasome inhibitor bortezomib (VELCADE; Millennium Pharmaceuticals and Johnson
& Johnson Pharmaceutical Research & Development) has revolutionized the treatment of mul-
tiple myeloma (MM) patients and has become a mainstay in the standard of care for both pre-
viously untreated [1] and relapsed [2, 3] patients with MM. A number of clinical and
laboratory features provide prognostic information for patients with MM, such as hypodipoidy
[4] and chromosomal translocations and deletions [5–7].
The gene expression profiles of plasma cells isolated from the bone marrow of MM patients
can predict the response to treatment with bortezomib [8, 9]. However, peripheral blood (PB)
biomarkers able to predict the response to bortezomib have not yet been identified, although
some factors are known to correlate with such responses, including hepatocyte growth factor
[10], thrombospondin [10], XBP-1 [11] and absolute lymphocyte counts [12].
In our previous study [13], we reported that phytohemagglutinin (PHA)-induced interleu-
kin-2 (IL2)mRNA levels in ex vivo whole blood obtained prior to bortezomib treatment could
predict the incidence of bortezomib-induced peripheral neuropathy. In this study, we used the
same assay to predict the efficacy of bortezomib treatment in an expanded patient population.
Subjects and Methods
Patients
Eligible patients in this multicenter prospective study consisted of previously treated MM
patients or untreated patients with symptomatic MM, as described in our previous study [13].
All patients had to have measurable levels of M-proteins. The study was approved by the insti-
tutional review board or independent ethics committee at all participating institutions and was
conducted according to the principles of the Declaration of Helsinki and the International
Conference on Harmonization Guidelines of Good Clinical Practice. All patients provided
written informed consent for sample procurement. The following institutions participated in
this study: National Cancer Center Hospital; Saitama Medical Center, Saitama Medical Univer-
sity; Nagoya City University, Graduate School of Medical Sciences; Japanese Red Cross Medical
Center; University of Tokushima, Graduate School of Medical Sciences and Tokai University
School of Medicine (Acknowledgement section of the ms.). Clinical responses were assessed
according to the International Uniform Response Criteria [14].
Measurements
Eight-well strips containing 1.2 μL each of PHA (2 mg/mL), heat-aggregated immunoglobulin
G (HAG) (10 mg/mL), lipopolysaccharide (LPS) (0.5 mg/mL), zymosan A (ZA) (75 mg/mL) or
solvent phosphate-buffered saline (PBS) were delivered to each institution on dry ice. These
strips were kept frozen at -80°C. A 2 mL sample of heparinized PB was obtained from each
patient prior to treatment as well as 2–3 days (D2-3) and 1–3 weeks (W1-3) after intravenous
administration of the first dose of bortezomib during the first cycle. The blood was immedi-
ately delivered to the designated laboratory, 0.06 mL of PB was added to each well containing 3
strips (that is, in triplicate), and the strips were incubated for 4 hours at 37°C. The total blood
LPS-CXCL10 Predicts Responses to Bortezomib in Myeloma Patients
PLOS ONE | DOI:10.1371/journal.pone.0128662 June 26, 2015 2 / 11
Competing Interests: TW received honorarium from
Takeda Pharmaceutical Co., Ltd. MA received
honoraria from Janssen Pharmaceutical Co., Ltd. and
Takeda Pharmaceutical Co., Ltd. SI received
research funding and honorarium from Janssen
Pharmaceutical Co., Ltd. MM was an employee of
Hitachi Chemical Research Center, Inc. Both this
company and MM do not have any consultancy,
patent, products in development or marketed
products relevant to the results. This does not alter
the authors' adherence to all PLOS ONE policies on
sharing data and materials.
volume required was 0.9 mL (0.06 mL/well x 5 wells/strip x 3 strips). After incubation, the sam-
ples were stored at -80°C.
mRNA analysis
Purification of mRNA and cDNA synthesis were performed as described previously using leu-
kocyte capture filter plates and oligo(dT)-immobilized microplates [15,16] The cDNA was
used for real-time PCR [15,16]. Melting curves were analyzed to confirm that the PCR signals
were derived from a single PCR product, and the cycle threshold (Ct) value was determined
using analytical software (SDS, Thermo Fisher Scientific, Carlsbad, CA). The Ct values of the
treated samples were subtracted individually from the mean Ct values of the control samples to
calculate the ΔCt, and the fold increase was calculated as 2^(-ΔCt), as described previously
[15,16]. The mRNAs analyzed included β-actin (ACTB), IL2 and interleukin-6 (IL6), granulo-
cyte-macrophage colony-stimulating factor (GMCSF), interferon-γ (IFNG), tumour necrosis fac-
tor-α (TNFSF2), CCL chemokine 4 (CCL4) and CXCL chemokine 10 (CXCL10) [16]. mRNA
analysis and clinical data collection were performed separately at the different centers.
Statistical analyses
Parametric (t-test) and non-parametric (unpaired Mann-Whitney and paired Wilcoxon tests)
tests were used to compare mRNA levels between the two groups. p<0.05 were considered sig-
nificant. The statistical analyses were performed using Excel (Microsoft, Redmond, WA) and
Prism 6 (GraphPad Software, La Jolla, CA).
Results
Patients’ charasteristics
Between March 2010 and March 2012, a total of 83 patients (44 male and 39 female) were
enrolled from six centers. The median age of all patients was 63 years (Table 1). Fifty patients
were previously treated, and 33 patients were untreated. After excluding one patient who
died early from progressive disease, another who received additional treatment and another
who committed suicide, 80 patients were eligible for response analysis. The numbers of
patients who demonstrated complete response (CR), very good partial response (VGPR),
partial response (PR), stable disease (SD) and progressive disease (PD) were 5, 7, 33, 33 and
2, respectively.
mRNA analysis
Overall, 3,600 mRNA preparations and cDNA synthesis reactions were carried out (80 patients
x 5 stimulants x 3 time points x 3 [triplicate]). A total of 28,800 PCR reactions were performed
(3,600 cDNA samples x 8 genes).
Pretreatment higher induction of LPS/ZA-inducedGMCSF, LPS-induced
CXCL10, and LPS/PHA/ZA-induced CCL4mRNA in CR/VGPR
responders to bortezomib
The fold increase in LPS-induced GMCSF, CXCL10 and CCL4, PHA-induced CCL4 and ZA-
induced GMCSF and CCL4 were significantly higher in the CR and VGPR groups than in the
SD and PD groups, as determined by both parametric t-tests and non-parametric Mann-Whit-
ney tests, whereas the PR group exhibited an intermediate value (Fig 1). Moreover, 100, 67, 56,
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42 and 0% of patients showed more than 3-fold increases in LPS-induced CXCL10 (dotted line
in Fig 1).
Sustained suppression of LPS-induced CCCL10mRNA in CR/VGPR
responders to bortezomib
As shown in Fig 2, LPS-induced CXCL10mRNA expression was significantly suppressed 2–3
days after the first dose of bortezomib in all groups, as determined by both parametric (t-test)
Table 1. Patients Demographic and Baseline Characteristics.

































CR, complete response; ISS, International Staging System; NE, not evaluable; PD, progressive disease;
SD, stable disease; VGPR, very good partial response.
*Excluded were three patients not evaluable for response.
†According to the International Uniform Response Criteria (Durie et al, 2006).
‡One patient died of progressive disease early, another received additional chemotherapy, and the third
committed suicide.
doi:10.1371/journal.pone.0128662.t001
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and non-parametric (paired Wilcoxon test) tests, while the CR+VGPR group showed sustained
suppression even 1–3 weeks after treatment. This significant level of inhibition was only
observed for LPS-induced CXCL10.
Discussion
Currently, triple drug combinations are believed to be very effective for MM treatment based
on the results of several randomised clinical trials [1,17–23] and phase I/II studies [24, 25].
However, in some studies, the daily dose of bortezomib [1, 26–28] and the bortezomib admin-
istration schedule (namely, the dose density) [29–31] are reduced to avoid toxicity, despite the
fact that bortezomib accumulation is important for achieving improved survival [32]. Although
MM patients still experience relapse or progression even after triple drug combination therapy,
it is clear that better responses to initial therapy result in longer survival [33–36]. If we could
predict which patients will respond to bortezomib, we would be able to give priority to bortezo-
mib dose, rather than the other drugs, in combination regimens. Thus, it is important to pre-
dict whether patients will respond to bortezomib before initiation and whether bortezomib can
be used in consolidation [1, 37] or maintenance [29, 30, 38, 39] therapy.
This is the first report demonstrating the use of LPS-induced CXCL10mRNA levels as a bio-
marker for assessing the clinical response to bortezomib treatment in PB. We showed that
higher induction of CXCL10mRNA corresponded to very good responses (CR+VGPR),
whereas lower induction corresponded to poor responses (SD+PD); the values in the PR group
Fig 1. Ex vivomRNA induction in blood obtained prior to bortezomib treatment. The fold increase in (A) LPS-inducedGMCSF, (B) ZA-inducedGMCSF,
(C) LPS-induced CXCL10 (top panel), (D) PHA-inducedCCL4, (E) LPS-induced CCL4 and (F) ZA-inducedCCL4 (lower panel) mRNA in the CR, VGPR, PR,
SD and PD groups is shown. The statistically significant difference between the CR+VGPR and SD+PD groups is shown. t: Student’s t-test, M: Mann-
Whitney test. Dotted line: fold increase = 3. Samples showing a fold increase in ACTB (which was > 3) were removed from the analysis. Horizontal bars: the
mean values.
doi:10.1371/journal.pone.0128662.g001
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were variable. Moreover, LPS-induced CXCL10mRNA was significantly and continuously sup-
pressed in the good response group even 1–3 weeks after treatment, whereas in the other
groups, the suppressive activity was transient and CXCL10mRNA levels returned to the origi-
nal values. It could be argued that the best biomarker may be ZA-induced GMCSF because the
mean mRNA levels appeared to be higher in both the CR and VGPR groups than those in
other response groups. The range of LPS-induced CXCL10 expression in the CR group was
within the ranges of LPS-induced CXCL10 expression in both PR and SD groups, and lack of
overlap was seen in only the patients with CR versus the two patients with PD, although the lat-
ter was a small number. Similarly, LPS-induced CXCL10 expression in the VGPR group gener-
ally fell within the ranges seen in the patients with PR and those with SD. However, the
majority of MM patients will respond to bortezomib especially in case used as the first-line
treatment. Therefore, it is more important to distinguish the patients with PD after treatment
with bortezomib, which may have the mutations as to the proteasome pathway [40], from
responders to bortezomib rather than finding the difference in the response.
CXCL10, which was previously referred to as interferon γ-inducible 10 kDa protein (IP-10),
belongs to the C-X-C family of chemokines that cluster on human chromosome 4 (q12-21).
CXCL10 acts as a chemoattractant for human monocytes, activates T cells through binding to
the CXCR3 receptor and promotes T cell adhesion to endothelial cells [41]. CXCL10 also elicits
a Th1 cell-dominated anti-tumour inflammatory response that can inhibit plasmacytoma
growth [42]. Moreover, activated tumour-specific T cells that express CXCR3 were shown to
infiltrate CXCL10-expressing myeloma cells more efficiently than non-CXCL10-expressing
Fig 2. LPS-inducedCXCL10 expression before and after bortezomib treatment. Each point/line represents the fold increase in LPS-induced CXCL10
expression in each patient in the (A) CR+VGPR, (B) PR and (C) SD+PD groups. The statistically significant difference between the pretreatment (D0) and
2–3 days (D2-3) or 1–3 weeks (W1-3) after intravenous administration of the first dose of bortezomib during the first cycle groups is shown. t: Student’s t-test,
W: Wilcoxon test.
doi:10.1371/journal.pone.0128662.g002
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myeloma cells [43]. CCL4 is another chemotactic factor, and GMCSF is a growth factor for
antigen-presenting cells. Thus, the higher induction of CXCL10, CCL4 and GMCSFmRNA
exhibited by the good responder group (Fig 1) was not unexpected and suggests that these
patients may have greater anti-tumour immunity.
However, after bortezomib was administered to MM patients, CXCL10mRNA induction
was significantly suppressed, and sustained suppression correlated with good responses to
treatment (Fig 2). Usually bortezomib may be administerd to MM patients in combination
with dexamethasone (the same day as that of bortezomib administration and the subsequent
day) as used in the SUMMIT trial [44]. Actually the majority of the patients enrolled in this
study received dexamethasone (Table 1) in the above-mentioned way, although detailed data
were collected but not shown. In case of dexamethasone-naïve patients with MM, they can
still respond to dexamethasone. Consequently, we may not be able to distinguish the
responders to bortezomib from the responders to dexamethasone in 2–3 days after the first
dose of bortezomib. Therefore, the induced mRNA that caused demonstrable sustained sup-
pression may indicate more meaningful predictor of bortezomib responders. In addition, as
mentioned above, such triple combination as bortezomib, melphalan, and prednisone is
believed to be best among double to quadruple combinations and therefore used commonly,
and melphalan and prednisone will be given days 1–4 of each cycle [1, 17]. In those cases,
afore-mentioned, sustained suppression might become powerful tool of prediction although
further studies in this approach in combination trials is essential as a validation exercise for
theses assays to go forward.
This observation was likely not explained by the immunological activity of CXCL10, as
CXCL10 is also expressed in human myeloma cell lines [45] and is known to stimulate mye-
loma cell migration [46] and adhesion to bone marrow stromal cells [47]. Thus, MM cells may
be more susceptible to the bortezomib-induced inhibition of CXCL10mRNA expression than
immune cells. Moreover, when bortezomib was added to whole blood prior to LPS stimulation
Fig 3. Bortezomib-induced inhibition of LPS-inducedCXCL10mRNA ex vivo. Peripheral blood obtained
from 3 healthy volunteers was pre-treated with various concentrations of bortezomib for 1 h and then further
stimulated with LPS or PBS (as the control) for an additional 4 h. The fold increase in (A) ACTB and (B)
CXCL10 expression is shown. Each symbol represents a single individual.
doi:10.1371/journal.pone.0128662.g003
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ex vivo, CXCL10mRNA induction was inhibited in a dose-dependent manner (Fig 3). Thus,
LPS-induced CXCL10 expression in ex vivo blood samples could serve as a surrogate marker
for the effect of bortezomib in vivo.
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